Quick Answer
Upstream Bio, Inc. reported Stockholders Equity of $339.77 million for the year ending 2025.
- Upstream Bio, Inc. showed a decrease of -27.7% in Stockholders Equity from 2024 to 2025.
- This data is from Upstream Bio, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$107.91 million | Q2 2023: -$109.87 million | Q3 2023: -$112.20 million | Q1 2024: -$133.41 million | Q2 2024: -$146.61 million | Q3 2024: -$160.31 million | Q1 2025: $445.61 million | Q2 2025: $408.74 million | Q3 2025: $378.58 million.
- Over the full 4 years of available data (2022 to 2025), Upstream Bio, Inc.'s Stockholders Equity has grown by 420.1%.
- Historical annual values: Fiscal year 2025: $339.77 million | Fiscal year 2024: $469.85 million | Fiscal year 2023: -$123.13 million | Fiscal year 2022: -$106.16 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: